Clearmind Medicine announces 1-for-30 reverse share split

Clearmind Medicine will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing November 28, 2023. The reverse share split was approved by the Company’s shareholders at the Company’s general shareholders meeting held on November 14, 2023 and subsequently resolved by the Company’ board of directors. Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged, which as of the date hereof is unlimited. The reverse split will adjust the number of issued and outstanding Common Shares of the Company from 18,221,419 Common Shares to 607,381 Common Shares.